COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION

被引：0
|
作者：
Ward, M. A. [1 ]
Biddle, A. K. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A121 / A121
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
  • [42] ANALYSIS OF COST-EFFECTIVENESS OF WARFARIN VS. DABIGATRAN ETEXILATE IN ATRIAL FIBRILLATION IN ECUADOR
    Penaherrera, E.
    Tettamanti, D.
    Aguirre, F.
    Puyol, L. F.
    Cardenas, E.
    Torres, G.
    Herran, S.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
  • [43] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
    Chang, Chia-Hsien
    Yang, Yea-Huei Kao
    Chen, Jyh-Hong
    Lin, Li-Jen
    THROMBOSIS RESEARCH, 2014, 133 (05) : 782 - 789
  • [44] Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong
    Ho, Jason C. S.
    Chang, Andy M.
    Yan, Bryan P.
    Yu, Cheuk Man
    Lam, Yat Yin
    Lee, Vivian W. Y.
    CLINICAL CARDIOLOGY, 2012, 35 (12) : E40 - E45
  • [45] How Big Is the Impact of the Warfarin Cost on the Cost-Effectiveness of Rivaroxoban for Stroke Prevention in Atrial Fibrillation?
    Sanaei, Omid
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (09): : 1384 - 1385
  • [46] Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
    Lip, Gregory Y. H.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Chalkiadaki, Corina
    Liu, Xianchen
    Kuznik, Andreas
    Lawrence, Jack
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2476 - 2488
  • [47] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [48] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [49] Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
    Kamae, Isao
    Hashimoto, Yoichiro
    Koretsune, Yukihiro
    Tanahashi, Norio
    Murata, Tatsunori
    Phatak, Hemant
    Liu, Larry Z.
    Tang, Ann C.
    Wang, Peter Feng
    Okumura, Ken
    CLINICAL THERAPEUTICS, 2015, 37 (12) : 2837 - 2851
  • [50] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
    Kansal, Anuraag R.
    Sorensen, Sonja V.
    Gani, Ray
    Robinson, Paul
    Pan, Feng
    Plumb, Jonathan M.
    Cowie, Martin R.
    HEART, 2012, 98 (07) : 573 - 578
12345